Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AFDN divergent transcript (AFDN-DT)
- Target
- AFDN-DT
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein coding RNA, Other
01
Overview
AFDN divergent transcript (AFDN-DT) is a long non-coding RNA gene situated upstream of the Afadin (AFDN) locus on chromosome 6. It is mainly located in the nucleus and exerts its tumor-suppressive effects by binding directly to chromatin and regulating the transcription of genes critical for cell proliferation, metastasis, and transformation, particularly in gastric cancer. This regulatory function involves interaction with transcription factor motifs and direct binding to promoters of important cancer-related genes (such as JUN, FOS, and EGR1). Repression of AFDN-DT correlates with enhanced cancer aggressiveness, while restoration of its expression (e.g., by DNA methylation inhibitors) has been linked to growth inhibition of cancer cells[1][5].
- Other names
- MLLT4 antisense RNA 1 (MLLT4-AS1)HGC6.4dJ431P23.3XBP1SBM (XBP1s binding micropeptide)C6orf123HGC6.2LINC01557dJ431P23.4Long intergenic non-protein coding RNA 1557LINC01558AFDN divergent transcript
02
Mechanism of action
Not applicable
03
Biological functions
Transcriptional regulationChromatin binding and interaction with transcription factors and histonesTumor suppression
04
Disease associations
Cancer (mainly gastric cancer, also reported in oral squamous cell carcinoma)
05
Biomarkers
Reduced AFDN-DT expression is associated with poor prognosis in gastric cancer, suggesting a potential role as a prognostic biomarker
Beyond the preview
Go deeper on AFDN divergent transcript (AFDN-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFDN divergent transcript (AFDN-DT).